Genetically engineered malaria vaccine demonstrates 87% efficacy in phase 1 trial
The novel, genetically attenuated whole parasite PfSPZ-LARC2 Vaccine for malaria achieved an 87% efficacy rate in preventing infection during a recent phase 1 trial.
Read original article on The Medical News →